Bristol-Myers Squibb

Bristol-Myers Squibb (NYSE:BMY - Free Report) - Equities researchers at Cantor Fitzgerald lowered their FY2023 earnings per share estimates for shares of Bristol-Myers Squibb in a research report issued on Friday, July 28th. Cantor Fitzgerald analyst O. Brayer now forecasts that the biopharmaceutical company will earn $7.50 per share for the year, down from their…

News of a $50 million investment by artificial intelligence (AI) leader Nvidia Co. (Nasdaq: NVDA) into AI-powered drug discovery company  Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) more than doubled share prices. It also shined the spotlight on AI-powered drug discovery and the potential for quicker, better and more personalized drug therapies being developed using AI. One…

Learn the Insider Secrets of what the Top Hedge Funds are doing TODAY to maximize their upside and gains. AI is clearly the most buzzworthy topic of the year but it’s not new. It’s been around for a very long time. Phones and social media don’t wow with innovation anymore but AI can and will. Unsee…

By Michael Erman (Reuters) -Bristol Myers Squibb on Thursday said its second-quarter sales fell more than expected and cut its full-year forecasts as two of its top drugs, the blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition. The company said sales of Revlimid and another blood cancer drug Pomalyst were also hurt…

Securing FDA approvals last year for three drugs that each have peak sales potential of $4 billion bodes well for the long-term future of Bristol Myers Squibb. | Bristol Myers Squibb is entering a dark stage. In the second quarter, the company's three top-selling drugs—Eliquis, Revlimid and Opdivo—all meaningfully missed analysts’ expectations. And it's projecting…

New AI guidance software will allow more medical professionals to conduct cardiac ultrasound in multiple care settings expanding patient access to cardiac imaging TEL AVIV, Israel , July 27, 2023 /PRNewswire/ -- Today, UltraSight, a digital health pioneer transforming cardiac imaging through the power of artificial intelligence, announced that it has…

Bristol-Myers Squibb Company  press release (BMY): Q2 Non-GAAP EPS of $1.75 misses by $0.24.Revenue of $11.2B (-5.8% Y/Y) misses by $610M.Reports Second Quarter Revenue Growth...

By Ed Miseta, Chief Editor, Clinical Leader Follow Me On Twitter @EdClinical In 2022, Bristol Myers Squibb (BMS) announced plans to work with AI developer Owkin to design and optimize cardiovascular…

Statistically Speaking, This Is the Best Age to Claim Social Security Benefits -- and It's Not Even Close 4 Unsurpassed Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip 2 High-Yield Dividend Stocks to Buy Hand Over Fist and Hold Forever This Dividend Growth Machine Just Announced Another 20%…

Bristol Myers Squibb is launching a new ad for its blockbuster-in-waiting drug Zeposia as it focuses on a new future for those with ulcerative colitis (UC). | Bristol Myers Squibb is launching a new ad for its blockbuster-in-waiting drug Zeposia as it focuses on a new future for those with ulcerative colitis (UC).

The retirement of Novartis’ long-standing chief communications officer Michael Willi has created a domino effect of changes within its corporate and communications business. | The retirement of Novartis’ long-standing chief communications officer Michael Willi has created a domino effect of changes within its corporate and communications business.

Bloomberg TV anchor Lisa Abramowicz often refers to “AI hype” and “the frenzy over AI,” implying that investor enthusiasm for the technology is excessive and unwarranted. However, I strongly believe that AI will significantly transform the majority of companies, backed by compelling evidence. As a result, I think that investors can profit tremendously over the…